Trial intelligence / Profile preview

Dupilumab in moderate to severe atopic dermatitis

NCT04447417Phase 4Completed

Sponsor
Sanofi
Start
Jul 2020
Primary completion
Jun 2021
Modality
Monoclonal Antibodies
Countries
2
01

Overview

A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Started Jul 2020; status: completed.

02

Drugs

03

Conditions

atopic dermatitis (AD)

Beyond the preview

Go deeper on NCT04447417.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04447417.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call